

[First Reprint]

# SENATE JOINT RESOLUTION

## No. 115

# STATE OF NEW JERSEY

## 218th LEGISLATURE

INTRODUCED DECEMBER 10, 2018

**Sponsored by:**

**Senator JOSEPH PENNACCHIO**

**District 26 (Essex, Morris and Passaic)**

**Senator JOSEPH F. VITALE**

**District 19 (Middlesex)**

**Co-Sponsored by:**


**Senators A.R.Bucco, Rice, Thompson, Gopal and Greenstein**

**SYNOPSIS**

Establishes New Jersey Pharmacogenomics Commission.

**CURRENT VERSION OF TEXT**

As reported by the Senate Health, Human Services and Senior Citizens Committee on March 4, 2019, with amendments.



**(Sponsorship Updated As Of: 3/15/2019)**

1 **A JOINT RESOLUTION** establishing the New Jersey  
2 Pharmacogenomics Commission.

3  
4 **BE IT RESOLVED** by the Senate and General Assembly of the  
5 State of New Jersey:

6  
7 1. a. There is established the New Jersey Pharmacogenomics  
8 Commission. The commission shall be responsible for examining  
9 **1**Pharmacogenomics pharmacogenomics<sup>1</sup>, which is the study of  
10 the relationship between a person’s specific genetic makeup and the  
11 effectiveness or toxicity of medications used to treat any health-care  
12 related issue. The commission’s examination shall include, but  
13 shall not be limited to:

14 (1) costs related to **1**Pharmacogenomic pharmacogenomic<sup>1</sup>  
15 testing currently and in the future;

16 (2) how implementing **1**Pharmacogenomics  
17 pharmacogenomics<sup>1</sup> may benefit prescribers, patients, and the State;

18 (3) various applications for **1**Pharmacogenomics  
19 pharmacogenomics<sup>1</sup> outside of medicine, such as the opioid crisis  
20 and others;

21 (4) the relationship between **1**Pharmacogenomics  
22 pharmacogenomics<sup>1</sup> applications in **1**Personalized Medicine  
23 personalized medicine<sup>1</sup>;

24 (5) the results of previous studies on prescribing medicines and  
25 treatments based on **1**Pharmacogenomic pharmacogenomic<sup>1</sup>  
26 science;

27 (6) methods of educating patients and prescribers on prescribing  
28 medicine and treatment based on genetic makeup;

29 (7) the relationship of **1**Pharmacogenomics  
30 pharmacogenomics<sup>1</sup> in the reduction of the number of deaths,  
31 disabilities, and hospitalization from **1**Adverse Drug Events  
32 adverse drug events<sup>1</sup>; and

33 (8) the expected costs and benefits from implementing  
34 **1**Pharmacogenomics pharmacogenomics<sup>1</sup> in the short-term and  
35 long-term.

36 b. The commission shall consist of **1**ten 11<sup>1</sup> members, to be  
37 appointed by the Governor as follows: a representative from the  
38 Department of Health; a representative from the Division of  
39 Pensions and Benefits in the Department of the Treasury; a  
40 representative from Rutgers Medical School; a representative from  
41 Rutgers School of Pharmacy; a representative from Fairleigh  
42 Dickinson School of Pharmacy and Health Sciences; a  
43 representative from the New Jersey Hospital Association; a  
44 representative from the Medical of Society New Jersey; a

**EXPLANATION** – Matter enclosed in bold-faced brackets **[thus]** in the above bill is not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

Matter enclosed in superscript numerals has been adopted as follows:

<sup>1</sup>Senate SHH committee amendments adopted March 4, 2019.

- 1 representative from the New Jersey Pharmacists Association; a  
2 representative from the Department of Military and Veterans  
3 Affairs; 1a representative from BioNJ;<sup>1</sup> and a professor of genetics.
- 4 c. Vacancies in the membership of the commission shall be  
5 filled as provided for the original appointments.
- 6 d. The commission shall organize as soon as practicable  
7 following the appointment of its members and shall select a  
8 chairperson from among the members. The chairperson shall  
9 appoint a secretary who need not be a member of the commission.
- 10 e. Members of the commission shall serve without  
11 compensation, but shall be reimbursed for necessary expenses  
12 incurred in the performance of their duties as members of the  
13 commission within the limits of funds appropriated or otherwise  
14 made available to the commission for its purposes.
- 15 f. The commission shall be entitled to call to its assistance and  
16 avail itself of the services of the employees of any State, county, or  
17 municipal department, board, bureau, commission, or agency as it  
18 may require and as may be available to it for its purposes.
- 19 g. The Department of Health shall provide staff support to the  
20 commission.
- 21 h. (1) No later than six months after organization, the  
22 commission shall hold at least two public hearings, one each in  
23 northern New Jersey and southern New Jersey.
- 24 (2) For the purposes of this subsection, “northern New Jersey”  
25 means Bergen, Essex, Hudson, Hunterdon, Middlesex, Morris,  
26 Passaic, Somerset, Sussex, Union, and Warren counties; and  
27 “southern New Jersey” means Atlantic, Burlington, Camden, Cape  
28 May, Cumberland, Gloucester, Mercer, Monmouth, Ocean, and  
29 Salem counties.
- 30 i. No later than six months after organization, the commission  
31 shall submit to the Governor, and to the Legislature pursuant to  
32 section 2 of P.L.1991, c.164 (C.52:14-19.1), a report of its findings  
33 and recommendations for legislative, executive, or any other action  
34 as may be appropriate. The commission shall expire upon  
35 submission of its report.
- 36
- 37 2. This joint resolution shall take effect immediately.